Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma

The anti-GD2 antibody dinutuximab beta (Qarziba(®)) has been added to the present standard of care for patients with high-risk neuroblastoma in Europe based on the positive results obtained in different studies. In both the first-line and relapsed/refractory settings, treatment with dinutuximab beta...

Descripción completa

Detalles Bibliográficos
Autores principales: Balaguer, Julia, García Hidalgo, Laura, Hladun, Raquel, Márquez Vega, Catalina, Pérez Alonso, Vanesa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928814/
https://www.ncbi.nlm.nih.gov/pubmed/36504394
http://dx.doi.org/10.1007/s11523-022-00930-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928814/
https://www.ncbi.nlm.nih.gov/pubmed/36504394
http://dx.doi.org/10.1007/s11523-022-00930-w

Ejemplares similares